FDA Brief

Warning letters Drugs

FDA warning letter to

Daniel Fred Goodman, M.D./Goodman Eye Center

High riskIssued Jul 14, 2022Posted Jul 26, 2022Center for Drug Evaluation and Research | CDER

FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

What happened

FDA inspected the clinical site between November 29 and December 13, 2021, and reviewed Dr. Goodman's conduct as sponsor-investigator of a clinical investigation of an investigational drug. FDA found the investigation began before an Investigational New Drug application (IND) was in effect, with four subjects enrolled and treated from September 17 to October 1, 2019. FDA also found two subjects enrolled without legally effective written consent and six minors enrolled without IRB-required written assent (a child's agreement).

What FDA found

  1. Started a clinical investigation of an investigational drug before submitting an IND and having it in effect.

    21 CFR 312.20(a), 312.20(b), and 312.40(a)
  2. Enrolled and treated four human subjects before the IND's effective date.

    21 CFR 312.40
  3. Failed to obtain legally effective written informed consent from two subjects before enrolling them.

    21 CFR 312.60, 50.20, and 50.27
  4. Failed to obtain the IRB-required written assent of six minors before enrolling them.

    21 CFR 312.60 and 50.55

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations and address the deficiencies. Failure to adequately address the matter may lead to regulatory action.

Who should pay attention

  • sponsor-investigators running clinical trials
  • IRBs and research sites enrolling minors
  • contract research organizations and study coordinators

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk